STAAR Surgical is trading at $30.37, up 11.78% in pre-market after adjusted earnings and revenue exceeded analyst expectations. - Third-quarter sales were $83.4 million and net income was $5.6 million. Sales grew 21% excluding a prior-year $25.9 million deferred China revenue item. - Management reaffirmed its full-year outlook. - The company highlighted its $50 million share repurchase authorization, citing confidence in the business and its share value.